Skip to content

Heart and circulatory system

Heart Disease in India’s Workforce: Claims, Lipid Screening, and What HR Can Do

Section titled “Heart Disease in India’s Workforce: Claims, Lipid Screening, and What HR Can Do”
Of all hospitalizations are heart claims
4.75%
Average cost per claim, the highest of any chapter
₹1,07,367
Total insurance spend over four years
₹39.40 Cr
Of screened employees have at least one abnormal lipid marker
97.3%

To understand heart health in the Indian workplace, it helps to view the organisation as a biological time-lapse. By analysing relative risk density across age cohorts, the data reveals how the silent lipid flags of a 24-year-old in a tech hub today are the direct precursors to high-severity claims two decades later. This chapter examines the trajectory across cardiovascular claims and lipid screening data from unique employees.

Section titled “What share of health insurance claims in India are heart-related?”

Cardiovascular disease does not begin at hospitalization. It begins with borderline LDL in a young employee who has no symptoms, no urgency and no follow-up. The ICMR study estimates that heart disease manifests 5 to 10 years earlier in South Asians than in Western populations, and 25% of acute myocardial infarctions in India occur in individuals under 40.

Our data shows both the end of this pipeline, hospitalization claims (₹39.40 crore in insurance spend), and its beginning: 97.3% of total screened employees with at least one abnormal lipid marker.

In mid-2025, 22 sudden cardiac deaths in a single Karnataka district, predominantly in individuals under 45, underscored the clinical reality of early-onset cardiovascular disease in Indian populations. India reports an estimated 4.5 million sudden cardiac deaths annually. South Asians carry a unique biological predisposition: metabolic syndrome prevalence runs 30 to 40% (vs 15 to 20% in Europeans), approximately 4% of the Indian population carries the MYBPC3 gene variant associated with cardiomyopathy, and BMI thresholds for obesity have been lowered from 25 to 23 for Asian populations, recognising that Indian bodies metabolise risk at lower weight thresholds.

Heart claims account for 4.75% of all hospitalizations. While smaller in volume than maternity, injuries, or infections, cardiovascular events carry the highest financial weight per event in this portfolio. Average cost per claim: ₹1,07,367, the highest of any other claim in our data. Total insurance spend across four years: ₹39.40 crore.

The INTERHEART study found that over 90% of premature cardiac events are attributable to nine modifiable risk factors: abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial stress, low fruit and vegetable intake, low physical activity and alcohol. All of them are addressable through workplace health programmes.

How much do heart claims cost in group health insurance?

Section titled “How much do heart claims cost in group health insurance?”

Heart disease is the most expensive preventable claim category in this portfolio. Two characteristics define the cost profile:

  • 1.50x cost multiplier: A parent’s heart claim averages ₹1,22,814, which is 50% more expensive than an employee cardiac admission at ₹81,761. In 2025 alone, parent cardiac claims averaged ₹1,40,696, as event severity has been rising year on year.
  • Ischemic heart disease is the dominant driver: This is true for both parents and employees. Ischemic conditions (heart attacks and angina) account for 48.0% of parent cardiac claims at ₹1,42,497 on average, the highest-cost sub-condition. But it is not the only one. Cerebrovascular disease (stroke, TIA) accounts for 19.0% of parent claims, and other heart diseases, including cardiomyopathy and cardiac arrest, account for a further 11.6%. Parent cardiac events are not a single-condition story.

Which heart conditions drive the most claims?

Section titled “Which heart conditions drive the most claims?”
Sub-condition % of chapter Average cost What it means
Ischemic heart diseases (heart attacks, angina) 48% ₹1,22,299 Dominant condition. Sudden, high-cost, ICU-level events.
Cerebrovascular diseases (stroke, TIA) n/a ₹1,12,999 Growing faster than ischemic. Long recovery, disability risk.
Other circulatory system diseases 11% ₹92,617 Peripheral vascular disease, vascular insufficiency.
Hypertensive diseases 12% ₹42,222 Upstream feeder. Today’s hypertension is tomorrow’s heart attack.
Other heart diseases (cardiomyopathy, cardiac arrest) 11% ₹1,14,376 High cost per case; complex acute events.
Rheumatic and pulmonary (rare) 1% ₹2,22,462 Very low volume but highest average cost in the chapter.

Ischemic heart disease accounts for 48% of all cardiovascular claims and carries an average cost of ₹1.22 lakh per claim. These are acute, high-severity events (heart attacks and unstable angina) that dominate both volume and financial impact. They define today’s spend.

However, the more important shift is happening upstream. Hypertensive disease incidence has increased from 0.06 to 0.35 per 1,000 lives since 2022, nearly a sixfold rise even after adjusting for enrolment growth. While raw claims increased sharply off a low base, the incidence-adjusted view confirms this is not just population expansion. Risk itself is rising. Hypertension rarely drives large claims immediately. It builds silently over time. Uncontrolled blood pressure progresses into ischemic heart disease and stroke, the very conditions already anchoring this chapter’s costs.

The number of cases has plateaued at about 2.8 per 1,000 covered lives. But the average cost per case jumped 30% in just one year, from ₹96,352 to ₹1,25,381. Fewer new cases doesn’t mean lower costs. The cases that do happen are getting more serious and more expensive.

Why do men file more heart claims than women?

Section titled “Why do men file more heart claims than women? ”

In claims data, men account for 69.2% of cardiac hospitalizations at 2.88 per 1,000, versus 30.8% for women at 1.63 per 1,000. But this overall male dominance masks one of the most important gender dynamics in the dataset: the reversal after age 41.

Who % of heart claims Incidence (per 1,000) Average cost per claim What it means
Male (overall) 69% 2.88 ₹1,13,113 Dominant across all ages under 41.
Female (overall) 31% 1.63 ₹93,965 Lower overall rate, but overtakes men after menopause.

The gender flip after 41 is striking. Men dominate 2 to 3x in every group under 40, then women overtake at a 0.79x M:F ratio. This reflects the post-menopausal loss of estrogen’s cardioprotective effect. National data confirms this pattern: CVD prevalence in Indian women (14%) actually exceeds men (12%) in the adult population overall. About 4% of the Indian population carries the MYBPC3 gene defect linked to sudden cardiac arrest, a mutation unique to South Asians that remains silent until cellular repair mechanisms decline with age.

What do lipid screenings reveal about future heart claims?

Section titled “What do lipid screenings reveal about future heart claims?”

Cardiovascular risk in our data is front-loaded. The 20 to 30 age group accounts for 41.6% of all lipid abnormalities, despite having the lowest individual rate of abnormality per person screened. This is because the 20 to 30 cohort is the largest group in the workforce. The sheer number of young employees with lipid dysregulation creates a volume of early-stage risk that, if unmanaged, will convert to clinical cardiac events over the next decade.

Age group % of all abnormals Abnormality rate (per screened) M:F ratio What it means
20–30 41.6% (largest share) 36.10% 2.08 (male dominant) Highest volume cohort. Entry point of long-term cardiac risk.
31–35 21.60% 42.5% (rising rate) 2.57 Risk consolidating. Steepest acceleration in multi-marker clustering.
36–40 9.90% 44.1% (highest rate) 2.74 Transition window. Subclinical risk beginning to convert to clinical events.
41+ 26.90% 41.40% 0.73 (female dominant) Women overtake men. Post-menopausal lipid surge. Risk converging with parent claims.

Two important patterns emerge from the data.

First, while the largest number of abnormalities are in employees aged 20 to 30, the individual risk increases with age. The abnormality rate rises from 36.1% in employees aged 20 to 30 to 44.1% in those aged 36 to 40. This indicates that early abnormalities become more severe and are more likely to convert into clinical disease over time.

Second, the gender pattern shifts with age. Men dominate early risk, with a male-to-female ratio of 2.08 in the 20 to 30 group, rising to 2.74 in the 36 to 40 group. However, after age 41, this reverses, with women showing higher abnormality rates. This shift is linked to hormonal changes after menopause, which increase cardiovascular risk in women.

Employees aged 20 to 30 represent the earliest stage of the cardiac risk pipeline and the most important opportunity for prevention. The parents hospitalised with heart disease today were once employees in this same age group with similar unmanaged abnormalities. Early identification and intervention at this stage can significantly delay or prevent future cardiac events.

At what age do cholesterol abnormalities start in Indian employees?

Section titled “At what age do cholesterol abnormalities start in Indian employees?”

97.3% reflects the compound effect of factors like sedentary work, high-sodium diet, chronic stress, inadequate sleep and a metabolic predisposition that makes South Asian populations uniquely vulnerable to lipid imbalance.

The average flagged individual carries multiple concurrent abnormal markers, indicating systemic metabolic dysfunction rather than isolated readings. The most prevalent abnormality is HDL, the protective cholesterol, which is flagged in 67.8% of tests. Low HDL is both a direct cardiac risk factor and a marker for the broader metabolic syndrome pattern common in desk-bound, high-stress Indian professional environments.

Screened employees with an abnormal or borderline lipid marker

  • Abnormal or borderline
  • Highlighted
View as table
CategoryAbnormal or borderline
HDL (protective cholesterol)67.8%
Total cholesterol / HDL ratio52.4%
LDL / HDL ratio48.7%
LDL (bad cholesterol)47.6%
Non-HDL cholesterol35%
Triglycerides26.7%
VLDL21.7%
Total cholesterol18.2%
Source: Pazcare health check-up data.
  • HDL: Low HDL is the most prevalent marker. Sedentary lifestyle and diet driven.
  • Total cholesterol / HDL ratio: The most direct cardiac risk ratio; over half the workforce is elevated.
  • LDL / HDL ratio: The bad-to-good cholesterol balance is off in nearly half of those tested.
  • LDL: Nearly half with elevated LDL, the primary driver of arterial plaque.
  • Non-HDL cholesterol: A broader atherogenic marker, more sensitive than LDL alone.
  • Triglycerides: Linked to belly fat, high-carb diet and alcohol. Skews heavily male.
  • VLDL: Carries triglycerides. Male-dominant. A metabolic syndrome signal.
  • Total cholesterol: The lowest flagging rate, but in the context of HDL and LDL still meaningful.

Which Indian cities have the highest cardiovascular risk? (

Section titled “Which Indian cities have the highest cardiovascular risk? (”

Cardiovascular screening risk differs across urban technology centres, with each city presenting a distinct age and gender profile. This may reflect underlying differences in awareness, diet, activity or lifestyle.

City 20–30 30–35 35–40 41+ M:F What it means
Bangalore 45% 22% 10% 23% 1.79 Largest cohort. Young skew. Highest absolute volume of abnormals.
Mumbai 35% 27% 11% 27% 1.47 Highest 30–40 density (38%). Closest to clinical intervention.
Hyderabad 50% 24% 5% 21% 1.83 Youngest risk skew. Longest intervention runway.
Lucknow 36% 19% 10% 35% 1.35 Oldest skew of any city. Highest near-term conversion risk.
Ahmedabad 47% 19% 15% 20% 2.37 Sharpest gender imbalance. Male-targeted programming.
  • Mumbai: Highest density in the 30 to 40 transition window (approximately 38% of risk). This cohort is closest to clinical conversion, making Mumbai the highest near-term claims risk among the cities profiled.
  • Hyderabad: 50% of abnormalities in the 20 to 30 cohort, the youngest risk skew and the longest intervention runway in the dataset.
  • Ahmedabad: Sharpest gender imbalance at a 2.37x M:F ratio, indicating a male-dominated metabolic risk profile requiring gender-targeted interventions.

Why is heart disease appearing earlier in working-age employees?

Section titled “Why is heart disease appearing earlier in working-age employees?”

While parent populations dominate cardiac claims, the presence of employee cardiac admissions is clinically significant. This reflects delayed lifestyle intervention, prolonged sedentary behavior and unmanaged metabolic markers.

When cardiac events begin appearing in working-age employees, they indicate that risk curves are shifting left, compressing timelines between exposure and failure.

Cardiac claims create disproportionate organizational impact:

  • Sudden, high-acuity hospitalizations
  • Extended medical leave
  • Long-term medication and follow-up costs
  • Increased caregiver burden for employees with affected parents

From an insurance perspective, cardiac events materially influence claim severity metrics, loss ratios and renewal negotiations. Even a small number of cardiac claims can reshape a group’s risk profile.

How can HR reduce heart disease risk and claims?

Section titled “How can HR reduce heart disease risk and claims?”

Heart hospitalizations don’t happen suddenly. They are the result of years of unmanaged risk like abnormal cholesterol and high blood pressure. By the time someone is hospitalised, the prevention window is already closing. That’s why HR action must focus on identifying and managing risk early.

1. Act on lipid screening results: report delivery is not intervention

Section titled “1. Act on lipid screening results: report delivery is not intervention”

In most organizations, employees who receive abnormal results in their health check-ups only receive a PDF, read the colour columns, see nothing marked critical and move on. That is not a screening programme. It is a documentation exercise. HRs should ensure:

  • Doctor follow-ups for employees with abnormal results, especially high LDL or poor cholesterol ratios, within 30 days of screening
  • Prioritization of high-risk employees, especially those with multiple abnormal markers
  • Annual re-screening for employees with borderline results, as risk can worsen quickly without intervention
  • Focused outreach to employees aged 36 to 40, as this group is closest to developing clinical heart disease

Screening only works if it leads to action. Otherwise, it simply documents risk without reducing it.

2. Treat hypertension management as cardiac prevention

Section titled “2. Treat hypertension management as cardiac prevention”

Hypertension is the single biggest driver of heart attacks and stroke. In this dataset, hypertension cases grew 20.2x, making it the fastest-growing cardiac risk factor. HRs should ensure:

  • Blood pressure checks are included in every health camp, along with cholesterol and glucose
  • Coverage for hypertension medication and follow-ups, so cost does not prevent treatment
  • Focused hypertension management for parents, who have the highest cardiac risk
  • Stress management programmes, as chronic workplace stress directly increases cardiovascular risk

Managing hypertension early prevents future hospitalizations.

3. Build city-specific programmes, not national campaigns

Section titled “3. Build city-specific programmes, not national campaigns”

Cardiac risk differs significantly by city, workforce age and gender mix. A generic national wellness programme will not address local risk patterns effectively. For example:

  • Cities with older workforces need stronger clinical screening and hypertension management
  • Cities with younger workforces should focus on prevention through lifestyle, nutrition and physical activity
  • Cities with higher male risk need targeted interventions around triglycerides, obesity and physical activity
  • Cities with high mid-career risk (30 to 40 age group) offer the fastest opportunity to reduce future cardiac claims

Programmes should reflect the actual risk profile of each workforce, not a one-size-fits-all approach.

4. Design for the gender reversal after 41

Section titled “4. Design for the gender reversal after 41”

Cardiac risk is often seen as a male problem, but this changes after age 40. Women’s cardiovascular risk rises sharply after menopause due to hormonal changes. HRs should ensure:

  • Access to menopause-related medical support, including specialist consultations
  • Health interventions focused on women aged 35 to 45, especially around physical activity and nutrition
  • Communication that raises awareness of heart risk in women, so symptoms and risks are not ignored

Ignoring women’s cardiac risk means missing the fastest-growing risk group.

  1. Pazcare claims and health check-up data, as described in Methods and data sources.
  2. ICMR study on early-onset heart disease in South Asians, as cited in the PDF.
  3. INTERHEART study on modifiable cardiac risk factors, as cited in the PDF. The PDF gives no links for these.